Literature DB >> 11072869

Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity.

A Hitomi1, S Satoh, I Ikegaki, Y Suzuki, M Shibuya, T Asano.   

Abstract

The aim of this study was to investigate the mechanisms of the pathogenesis of hyperviscosity following cerebral ischemia. Focal ischemia was produced by embolic occlusion of the right middle cerebral artery (MCA) in rats for 1 hour, followed by recirculation. Twenty-four hours after MCA occlusion, fasudil, a protein kinase inhibitor, was administered intraperitoneally. Blood samples were taken from the abdominal aorta, and viscosity was measured using a cone-plate viscometer. The viscosity of whole blood in the ischemic attack group was significantly increased compared with the sham operated group 24 hours after MCA occlusion. Fasudil dose-dependently and significantly decreased the blood viscosity, and reduced to the normal range after administration of 10 mg/kg of fasudil (sham-operated rats, 5.17+/-0.05 cP; pre dose/ischemic rats, 6.05+/-0.08 cP; post dose/ischemic rats, 5.23+/-0.14 cP; 37.5 sec(-1)). Our findings suggest that cerebral ischemia induces a potent, systemic and long-lasting hyperviscosity, and that the inhibition of protein kinases, especially rho kinase, is efficacious in preventing this hyperviscosity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072869     DOI: 10.1016/s0024-3205(00)00781-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms.

Authors:  Hwa Kyoung Shin; Salvatore Salomone; E Michelle Potts; Sae-Won Lee; Eric Millican; Kensuke Noma; Paul L Huang; David A Boas; James K Liao; Michael A Moskowitz; Cenk Ayata
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-11       Impact factor: 6.200

Review 2.  Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

Authors:  Ming Dong; Bryan P Yan; James K Liao; Yat-Yin Lam; Gabriel W K Yip; Cheuk-Man Yu
Journal:  Drug Discov Today       Date:  2010-06-25       Impact factor: 7.851

Review 3.  RhoA/Rho-kinase and vascular diseases: what is the link?

Authors:  Kenia Pedrosa Nunes; Christine S Rigsby; R Clinton Webb
Journal:  Cell Mol Life Sci       Date:  2010-07-29       Impact factor: 9.261

4.  Rho-kinase inhibition improves ischemic perfusion deficit in hyperlipidemic mice.

Authors:  Hwa Kyoung Shin; Paul L Huang; Cenk Ayata
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-06       Impact factor: 6.200

5.  Increased leukocyte ROCK activity in patients after acute ischemic stroke.

Authors:  Steven K Feske; Farzaneh A Sorond; Galen V Henderson; Minoru Seto; Asako Hitomi; Koh Kawasaki; Yasuo Sasaki; Toshio Asano; James K Liao
Journal:  Brain Res       Date:  2008-12-25       Impact factor: 3.252

6.  Cerebral vasospasm pharmacological treatment: an update.

Authors:  Ioannis Siasios; Eftychia Z Kapsalaki; Kostas N Fountas
Journal:  Neurol Res Int       Date:  2013-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.